New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
16:24 EDTFATEFate Therapeutics announces FDA clearance of IND for PROHEMA
Fate Therapeutics announced that the FDA has cleared its Investigational New Drug Application, or IND, for the clinical development of PROHEMA in pediatric patients undergoing hematopoietic stem cell transplantation for the treatment of inherited metabolic disorders, or IMDs. The FDA's clearance of the IND allows the company to begin expanding its clinical investigation of PROHEMA into rare, non-malignant disorders. The company plans to initiate enrollment of the PROVIDE trial in pediatric patients with IMDs in Q4.
News For FATE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
06:18 EDTFATEFate Therapeutics 6M share Secondary priced at $5.00
Leerink and BMO Capital acted as joint book running managers for the offering.
May 18, 2015
16:10 EDTFATEFate Therapeutics files to sell 6M shares of common stock
Fate Therapeutics intends to use the net proceeds from the offering for clinical development and research activities, working capital and other general corporate purposes. Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Wedbush PacGrow and H.C. Wainwright & Co., LLC are acting as co-managers

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use